Innovative Diagnostic Offerings Sequenom Laboratories specializes in advanced prenatal genetic testing with branded solutions such as MaterniT Genome and VisibiliT, allowing them to provide comprehensive early diagnosis options for obstetric care providers. This focus on cutting-edge non-invasive prenatal testing (NIPT) positions them as a leader in high-value diagnostic services.

Strong Tech Infrastructure The company's use of modern web technologies and laboratory accreditation (CAP and CLIA) highlights their commitment to technological excellence and regulatory compliance, creating a compelling value proposition for partners seeking reliable, scalable genetic diagnostics.

Market Growth Opportunities With a consistent track record of product launches since 2011 and recent expansion into broader chromosome screening with MaterniT Genome NIPS, Sequenom is positioned to capitalize on the increasing demand for comprehensive and non-invasive prenatal testing services.

Robust Financial Backing Having secured $360 million in funding and attracted substantial equity and debt investment, the company demonstrates strong financial health and growth potential, making it an attractive partner for collaborations, licensing, or distribution opportunities.

Industry Strategic Acquisition The acquisition by LabCorp in 2016 for over $370 million not only underscores the company's valuable market position but also indicates active industry consolidation, suggesting opportunities for strategic partnerships or integrations with healthcare providers seeking advanced genetic diagnostics.